Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition
BackgroundDedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel treatment options.Case descriptionThis report examines the efficacy and safety of sequential pre-treat...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1518775/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527136421150720 |
|---|---|
| author | Johannes M. Waldschmidt Johannes M. Waldschmidt Lukas Haug Lukas Haug Christine Riedhammer Christine Riedhammer Christoph K. W. Deinzer Marcus Zimmermann Marcus Zimmermann Anke Heidemeier Anke Heidemeier Peter Raab Peter Raab Maximilian Rudert Maximilian Rudert Anne Hendricks Anne Hendricks Johan F. Lock Johan F. Lock Viktoria Buck Viktoria Buck Andreas Rosenwald Andreas Rosenwald Hermann Einsele Hermann Einsele Peter Reichardt Volker Kunzmann Volker Kunzmann Armin Wiegering Armin Wiegering Daniel Pink Daniel Pink K. Martin Kortüm K. Martin Kortüm |
| author_facet | Johannes M. Waldschmidt Johannes M. Waldschmidt Lukas Haug Lukas Haug Christine Riedhammer Christine Riedhammer Christoph K. W. Deinzer Marcus Zimmermann Marcus Zimmermann Anke Heidemeier Anke Heidemeier Peter Raab Peter Raab Maximilian Rudert Maximilian Rudert Anne Hendricks Anne Hendricks Johan F. Lock Johan F. Lock Viktoria Buck Viktoria Buck Andreas Rosenwald Andreas Rosenwald Hermann Einsele Hermann Einsele Peter Reichardt Volker Kunzmann Volker Kunzmann Armin Wiegering Armin Wiegering Daniel Pink Daniel Pink K. Martin Kortüm K. Martin Kortüm |
| author_sort | Johannes M. Waldschmidt |
| collection | DOAJ |
| description | BackgroundDedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel treatment options.Case descriptionThis report examines the efficacy and safety of sequential pre-treatment with the marine-derived alkaloid trabectedin followed by checkpoint inhibition using the anti-PD-1 antibody nivolumab in a 63-year-old male patient with unresectable retroperitoneal DDLPS. Treatment was initiated at the time of the seventh relapse as part of the NitraSarc phase 2 multicenter trial for inoperable soft tissue sarcoma conducted by the German Interdisciplinary Sarcoma Group (GISG-15, NCT03590210). The patient demonstrated an immediate tumor response, and in combination with minor surgery, achieved R0 resection status, which was subsequently maintained without the need for further therapy for the past 52 months. Correlative molecular analyses revealed a sustained DNA damage repair machinery and downregulation of PD-1 protein expression in post-treatment tumor samples.ConclusionThis report provides exemplary insight on the feasibility and efficacy of sequential pre-treatment with trabectedin as a priming strategy for PD-1 inhibition in advanced DDLPS. Full trial results from NitraSarc are pending for publication. |
| format | Article |
| id | doaj-art-dc75985da14a49368e453b52e7b5410b |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-dc75985da14a49368e453b52e7b5410b2025-01-16T05:10:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.15187751518775Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibitionJohannes M. Waldschmidt0Johannes M. Waldschmidt1Lukas Haug2Lukas Haug3Christine Riedhammer4Christine Riedhammer5Christoph K. W. Deinzer6Marcus Zimmermann7Marcus Zimmermann8Anke Heidemeier9Anke Heidemeier10Peter Raab11Peter Raab12Maximilian Rudert13Maximilian Rudert14Anne Hendricks15Anne Hendricks16Johan F. Lock17Johan F. Lock18Viktoria Buck19Viktoria Buck20Andreas Rosenwald21Andreas Rosenwald22Hermann Einsele23Hermann Einsele24Peter Reichardt25Volker Kunzmann26Volker Kunzmann27Armin Wiegering28Armin Wiegering29Daniel Pink30Daniel Pink31K. Martin Kortüm32K. Martin Kortüm33Department of Internal Medicine II, University Hospital Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Pathology, University Hospital Würzburg, Würzburg, GermanyDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Internal Medicine VIII, University Hospital Tübingen, Tübingen, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Radiation Therapy, University Hospital Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Radiology, University Hospital Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Orthopaedic Surgery, König Ludwig Haus, University of Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Orthopaedic Surgery, König Ludwig Haus, University of Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Visceral Surgery, University Hospital Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Visceral Surgery, University Hospital Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Pathology, University Hospital Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Pathology, University Hospital Würzburg, Würzburg, GermanyDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Oncology, Helios Klinikum Berlin-Buch, Berlin, GermanyDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyDepartment of Visceral Surgery, University Hospital Würzburg, Würzburg, Germany0Department of Oncology and Palliative Care, Helios Klinikum Bad Saarow, Bad Saarow, Germany1Klinik und Poliklinik für Innere Medizin C, Universitätsmedizin Greifswald, Greifswald, GermanyDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, GermanyBavarian Cancer Research Centre (BZKF), Würzburg, GermanyBackgroundDedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel treatment options.Case descriptionThis report examines the efficacy and safety of sequential pre-treatment with the marine-derived alkaloid trabectedin followed by checkpoint inhibition using the anti-PD-1 antibody nivolumab in a 63-year-old male patient with unresectable retroperitoneal DDLPS. Treatment was initiated at the time of the seventh relapse as part of the NitraSarc phase 2 multicenter trial for inoperable soft tissue sarcoma conducted by the German Interdisciplinary Sarcoma Group (GISG-15, NCT03590210). The patient demonstrated an immediate tumor response, and in combination with minor surgery, achieved R0 resection status, which was subsequently maintained without the need for further therapy for the past 52 months. Correlative molecular analyses revealed a sustained DNA damage repair machinery and downregulation of PD-1 protein expression in post-treatment tumor samples.ConclusionThis report provides exemplary insight on the feasibility and efficacy of sequential pre-treatment with trabectedin as a priming strategy for PD-1 inhibition in advanced DDLPS. Full trial results from NitraSarc are pending for publication.https://www.frontiersin.org/articles/10.3389/fonc.2024.1518775/fullsarcomadedifferentiated liposarcomacheckpoint inhibitionPD-1immune microenvironment |
| spellingShingle | Johannes M. Waldschmidt Johannes M. Waldschmidt Lukas Haug Lukas Haug Christine Riedhammer Christine Riedhammer Christoph K. W. Deinzer Marcus Zimmermann Marcus Zimmermann Anke Heidemeier Anke Heidemeier Peter Raab Peter Raab Maximilian Rudert Maximilian Rudert Anne Hendricks Anne Hendricks Johan F. Lock Johan F. Lock Viktoria Buck Viktoria Buck Andreas Rosenwald Andreas Rosenwald Hermann Einsele Hermann Einsele Peter Reichardt Volker Kunzmann Volker Kunzmann Armin Wiegering Armin Wiegering Daniel Pink Daniel Pink K. Martin Kortüm K. Martin Kortüm Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition Frontiers in Oncology sarcoma dedifferentiated liposarcoma checkpoint inhibition PD-1 immune microenvironment |
| title | Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition |
| title_full | Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition |
| title_fullStr | Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition |
| title_full_unstemmed | Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition |
| title_short | Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition |
| title_sort | long term disease control in dedifferentiated liposarcoma a case report on trabectedin priming followed by pd 1 inhibition |
| topic | sarcoma dedifferentiated liposarcoma checkpoint inhibition PD-1 immune microenvironment |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1518775/full |
| work_keys_str_mv | AT johannesmwaldschmidt longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT johannesmwaldschmidt longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT lukashaug longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT lukashaug longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT christineriedhammer longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT christineriedhammer longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT christophkwdeinzer longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT marcuszimmermann longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT marcuszimmermann longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT ankeheidemeier longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT ankeheidemeier longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT peterraab longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT peterraab longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT maximilianrudert longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT maximilianrudert longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT annehendricks longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT annehendricks longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT johanflock longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT johanflock longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT viktoriabuck longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT viktoriabuck longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT andreasrosenwald longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT andreasrosenwald longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT hermanneinsele longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT hermanneinsele longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT peterreichardt longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT volkerkunzmann longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT volkerkunzmann longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT arminwiegering longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT arminwiegering longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT danielpink longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT danielpink longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT kmartinkortum longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition AT kmartinkortum longtermdiseasecontrolindedifferentiatedliposarcomaacasereportontrabectedinprimingfollowedbypd1inhibition |